Lumacaftor/ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis for approximately 1,500 children aged 2 to 5 with two copies of the F508del muta...
Vertex is to file its two latest cystic fibrosis drugs with Scotland’s drug cost watchdog in a bid for NHS reimbursement – but an ongoing row over price in England is still unresolved.
The US pharm...
Vertex is far-and-away the leader in cystic fibrosis drugmaking. Three approved therapies collectively raked in more than $2.1 billion this year, and the biotech is rapidly progressing with triple-com...
Pharmaceutical company VERTEX is now constructing the third stage of the Innovation and Production Complex in the Novoorlovskaya site, Special Economic Zone Saint-Petersburg.
Since the beginning of 2018, the residents of St. Petersburg Special Economic Zone (SEZ) have invested 1.787 billion rubles in their projects. Over the same period of last year, the residents invested 1.537 billion rubles.
VERTEX, a pharmaceutical company, is engaged in the construction of a laboratory and warehouse building, the second stage of its innovation and production facility on Novoorlovskaya site in St. Petersburg Special Economic Zone.
VERTEX published its official results for 2017. The pharmaceutical company demonstrated growth in four areas, including the output, number of pharmacies selling its products, product range, and revenue.
In two years following the launch of the pharmaceutical plant in late August 2015, VERTEX manufactured more than 100 million packages of drugs at this new site
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OK